DexCom (DXCM) said Thursday the Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring System for people at least 18 years old with diabetes in the US.
The device features 15.5 days of wear and provides easier glucose management with fewer monthly sensors and lower monthly waste, the company said.
The company said it is working with its insulin pump partners to ensure the wearable's compatibility with automated insulin delivery systems upon launch, which is expected to take place in the US in H2.
DexCom shares were up 9.6% in premarket activity Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。